Use of natural killer (NK) cells carrying an anti-spike mAb as covid19 therapy

Key facts

Disease
COVID-19
Funder
ANR
Principal Investigator
Martin VILLALBA
Research Location
France
Lead Research Institution
CHRU de Montpellier
Research Priority Alignment
N/A

Research Category
Therapeutics research, development and implementation
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

The CoviNK project, coordinated by Martin Villalba (UMR U1183 Institute of Regenerative Medicine and Biotherapies (IMRB) - CHRU de Montpellier), proposes to use natural killer cells (NK) carrying an anti-spike mAb, for the treatment of COVID -19. The team will be based on an expanded NK (eNK) production protocol patented by Inserm, and on a new approach for stably loading monoclonal antibodies (mAbs) on the membrane of NK cells, currently being developed for the cancer therapy.

Publicationslinked via Europe PMC

Last Updated:2 hours ago

View all publications at Europe PMC

Developing injury and illness epidemiology and surveillance in cycling (PhD Academy Award).

Effects of Hand-Rearing and Group Size on Chimpanzee (Pan troglodytes) Social Competence in Captivity.

Revisiting Spirituality in Physical Therapy Practice: Perceptions of US Practitioners.

Aflibercept for Wet Age-Related Macular Degeneration: A Prospective, Randomized Trial Comparing Treat-And-Extend and Fixed Bimonthly Dosing.

The Concentration and Duration of Lipopolysaccharide Stimulation Produce Different Cytokine Responses in an Ex Vivo Whole Blood Model in Horses.

History of Shrimp Farming and the Main Viral and Bacterial Diseases in Mexico.

Identification of Risk Factors in Patients with Recurrent Cystitis May Improve Individualized Management.

ISApl4, a New IS1595 Family Insertion Sequence Forming a Novel Pseudo-Compound Transposon That Confers Antimicrobial Multidrug Resistance in Actinobacillus pleuropneumoniae.